Risk calculators in glaucoma

Ameen, Sally; Javaid, Fatimah Zara; Cordeiro, M. Francesca

doi:10.1586/17469899.2016.1136213

Cited by 1 publication

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cognisance that a single biomarker may provide insufficient information has led to increasingly combining multiple biomarkers in other fields and development of risk calculators. This could be an exciting opportunity with ocular biomarkers, for example, OCT and ERG parameters, in a diagnostic calculator for PD . Furthermore, novel data analysis approaches for retinal images have been revolutionizing the ophthalmology field since the landmark paper by Gulshan and colleagues in 2016, which described automated retinopathy detection based on deep learning.…”

Section: Discussionmentioning

confidence: 99%

“…This could be an exciting opportunity with ocular biomarkers, for example, OCT and ERG parameters, in a diagnostic calculator for PD. 156,179,228,229 Furthermore, novel data analysis approaches for retinal images have been revolutionizing the ophthalmology field since the landmark paper by Gulshan and colleagues in 2016, 230 which described automated retinopathy detection based on deep learning. Machine/deep learning approaches could unveil novel, high-dimensional, quantitative measures to diagnose and objectively assess disease progression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Oculo‐visual abnormalities in Parkinson's disease: Possible value as biomarkers

et al. 2018

View full text Add to dashboard Cite

Parkinson's disease (PD) is one of the most common neurodegenerative disorders and the second leading cause of dementia worldwide. With an aging population, the prevalence of the disease has dramatically increased. Clinical management has advanced through recent developments in dopaminergic imaging and genetic risk profiling. However, early and accurate diagnosis of the disorder remains a challenge, largely because of the lack of noninvasive and inexpensive reliable diagnostic tests. Besides the well‐studied cerebral neurodegeneration that underlies the cardinal symptoms of PD (ie, bradykinesia, tremor, rigidity, and postural instability), ocular changes have also been described in PD, including visual dysfunction, pupil abnormality, lens opacity, and retinal neuronal loss and dysfunction. These ocular pathological processes are related to α‐synuclein deposition, and dopamine deficiency in the retina—mirroring the defining pathological features of PD in the brain. Together, these observations support the notion that the eye can serve as a window to the brain, providing clinicians with noninvasive methods to visualize disease. This review focuses on recent advances in the characterization of ocular changes in PD and their promising use as biomarkers in the eye, which can be potentially used for aiding in early diagnosis, tracking disease progression, and valuating novel therapeutic strategies. © 2018 International Parkinson and Movement Disorder Society

show abstract

Section: Discussionmentioning

confidence: 99%